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Background: Low back pain (LBP) is one of the most disabling and costly disorders affecting modern society, and
approximately 90% of patients are labelled as having non-specific LBP (NSLBP). Several interventions for patients
with NSLBP have been assessed in clinical trials, but heterogeneous reporting of outcomes in these trials has hindered
comparison of results and performance of meta-analyses. Moreover, there is a risk of selective outcome reporting bias.
To address these issues, the development of a core outcome set (COS) that should be measured in all clinical trials for a
specific health condition has been recommended. A standardized set of outcomes for LBP was proposed in 1998,
however, with evolution in COS development methodology, new instruments, interventions, and understanding
of measurement properties, it is appropriate to update that proposal. This protocol describes the methods used
in the initial step in developing a COS for NSLBP, namely, establishing a core domain set that should be measured
in all clinical trials.
Methods/Design: An International Steering Committee including researchers, clinicians, and patient representatives
from four continents was formed to guide the development of this COS. The approach of initiatives like Core Outcome
Measures in Effectiveness Trials (COMET) and Outcome Measures in Rheumatology (OMERACT) was followed. Participants
were invited to participate in a Delphi study aimed at generating a consensus-based core domain set for NSLBP. A list of
potential core domains was drafted and presented to the Delphi participants who were asked to judge which domains
were core. Participant suggestions about overlap, aggregation, or addition of potential core domains were addressed
during the study. The patients’ responses were isolated to assess whether there was substantial disagreement with the
rest of the Delphi panel. A priori thresholds for consensus were established before each Delphi round. All participants’
responses were analysed from a quantitative and qualitative perspective to ascertain that no substantial discrepancies
between the two approaches emerged.
Discussion: We present the initial step in developing a COS for NSLBP. The next step will be to determine which
measurement instruments adequately cover the domains.
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Low back pain (LBP) is the leading global contributor to
years lived with disability (YLDs) and the sixth global con-
tributor to disability-adjusted life years (DALYs) [1,2]. The
costs associated with LBP are high and they represent a
substantial burden to society [3]. Approximately 90% of pa-
tients with LBP are labelled as having non-specific LBP
(NSLBP), a diagnosis based on exclusion of a specific cause
or pathology [4]. A wide range of health interventions for
patients with NSLBP has been evaluated in clinical trials
[5]. The results of clinical trials addressing similar interven-
tions are often summarized in systematic reviews [6], but
authors of these reviews have reported that outcomes are
inconsistently measured and reported across trials [7,8].
This limits ability to compare findings between studies or
pool data for formal meta-analyses. Furthermore, inconsist-
ency can be the result of selective outcome reporting bias
(selective reporting of favourable outcomes) which can
strongly affect the conclusions of systematic reviews [9].
To reduce heterogeneity in outcomes measured across
clinical trials, development of core outcome sets (COSs)
in specific health conditions has been advocated [10]. A
COS is an agreed minimum set of outcomes that should
be measured and reported in all clinical trials for a particu-
lar health condition [11]. A COS might increase reporting
of important outcomes, reduce the risk of selective out-
come reporting, and increase the feasibility of conducting
meta-analyses [11]. The existence of a COS also ensures
that authors of clinical trials report on outcomes that are
relevant for all stakeholders [11]. Editors of Cochrane
Review Groups have agreed that the availability of COSs
would enhance reliability of the reviews [12].
In 1998, following an expert panel discussion held at the
second international LBP Forum (The Hague, Netherlands),
a proposal for a standardized set of outcomes in LBP
clinical research was published [13]. Five domains were
proposed for measurement (pain symptoms, back-related
function, generic wellbeing, disability social role, and satis-
faction with care) and specific measurement instruments
were recommended for each domain [13]. This proposal
has been highly cited and widely adopted over the years.
However, a workshop discussion among LBP researchers
during the 2012 twelfth LBP Forum (Odense, Denmark)
underlined the wish to update the existing recommenda-
tions considering recent advancements in the fields of COS
development and clinimetrics [11,14]. There were two pri-
mary reasons: to explore if relevant domains were missing,
and to critically appraise the recommended measurement
instruments in light of a large body of newer data on
measurement properties of instruments for LBP [15].
The aim of this study is to update the recommended
domains for LBP clinical research [13] through the devel-
opment of a COS. The Core Outcome Measures in Effect-
iveness Trials (COMET) [11] and the Outcome Measuresin Rheumatology (OMERACT) [16] initiatives provide
methodological guidance, involving a stepwise approach,
to development of a COS. The first step is to determine
which domains should be measured in all clinical trials
(‘what’ to measure, the ‘core domain set’), and the second
is to determine the instruments that should be used to
assess the domains (‘how’ to measure, the ‘core outcome
measurement set’) [11,17]. This protocol presents the
methods that will be adopted to reach a consensus on
the core domain set.
Our goals are to present a detailed context for reporting
in the results manuscript, and to provide a resource for
COS developers of any health condition. Despite encour-
agement of the COMET initiative to make COS protocols
publicly available, few have been published [18,19], provid-
ing the motivation for this paper.
Methods/Design
An International Steering Committee was formed to initi-
ate and support the development of this COS. Members
of the Steering Committee were chosen to represent vari-
ous disciplines, geographical areas, and types of expertise.
As a result, the Steering Committee includes 18 members
among whom: 14 are researchers from different disciplines
with ample experience in LBP clinical research (RD, CL,
RB, LC, NF, MG, BK, FK, CM, AP, WP, DT, MvT, RO),
three are experts in consensus-based research procedures
(CT, MB, DT), six are authors of several publications in
the field of clinimetrics (CT, RB, LC, FK, MG, RO), six are
healthcare providers involved in the management of
patients with LBP (MB, RB, LC, FK, AP, WP), and two
are patient representatives (TC, MS). The members repre-
sent Europe, Australia, and North and South America.
The project team consisted of one investigator (AC),
appointed to coordinate the day-to-day management of the
project, and three members of the Steering Committee
working at the same institution (CT, MB, RO). During
face-to-face meetings, the project team established the
methodology and addressed key aspects. The other mem-
bers of the Steering Committee were contacted by email
regarding critical decisions; when more than half of the
members agreed on a decision, this was followed unless
substantial and convincing arguments were raised by one
or more members in disagreement. Definitions of key con-
cepts and terms used in this study protocol follow those
recently outlined by the OMERACT initiative [17] and are
presented in Table 1.
Scope of this core outcome set
The Steering Committee recommended that this COS
should apply to measuring efficacy or effectiveness of
health interventions in clinical trials for patients with
NSLBP, defined as ‘low back pain not attributable to a
recognizable, known specific pathology (eg infection,
Table 1 Definitions of the terms used in this study protocol (Adapted from Boers et al. [17])
Concept Definition
Health Condition A situation of impaired health.
Health Intervention An activity performed by, for, with, or on behalf of a client(s) whose purpose is to improve individual
or population health, to alter or diagnose the course of a health condition, or to improve functioning.
Core Area An aspect of health or a health condition that needs to be measured to appropriately assess the effects
of a health intervention (core areas are broad concepts consisting of a number of more specific concepts
called domains).
Domain or Subdomain Component of core area: a concept to be measured, a further specification of an aspect of health,
categorized within a core area.
Outcome Any identified result in a (sub)domain arising from exposure to a casual factor or a health intervention.
Measurement Instrument A tool to measure a quality or quantity of a variable, in this context a (sub)domain or a contextual factor.
Outcome Measurement Instrument A measurement instrument chosen to assess outcome(s).
Core Domain Set For study of health interventions, the minimum set of domains and subdomains necessary to adequately
cover all core areas (fully measure all relevant concepts of a specific health condition within a specified
scope); it describes what to measure.
Core Outcome Measurement Set The minimum set of outcome measurement instruments that must be administered in each intervention
study of a certain health condition within a specified setting to adequately cover a corresponding core
domain set; it describes how to measure.
Scope The set of factors that describes the studies and circumstances to which the core outcome set will apply.
This is determined by the study questions and includes the health condition(s), target population,
interventions, and so forth.
Contextual Factor Variable that is not an outcome of the study, but needs to be recognized (and measured) to understand
the study results. This includes potential confounders and effect modifiers.
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terventions for NSLBP are targeted by this COS, re-
gardless of type, setting, or mode of administration. In
line with COMET definition [11], this does not imply
that primary outcomes of a clinical trial should always
be those of the COS or that outcome measures should
be restricted to the domains of the COS. However, do-
mains of this COS should be considered for inclusion in
all clinical trials on NSLBP, besides the measurement of
trial-specific domains. There is no intent that this COS
should be considered as a requirement for regulatory ap-
proval of drugs or devices, or that an intervention should
demonstrate benefits on all COS measures to be judged
efficacious or effective.
Other goals of this COS are to provide a recommenda-
tion on reporting of adverse events (AEs) in clinical trials
on NSLBP and to identify contextual factors (such as con-
founders and effect modifiers) that should be measured
alongside core domains (Table 1). However, it is out of our
scope to reach consensus on contextual factors that should
be measured and reported in all clinical trials. For measure-
ment and reporting of contextual factors, we refer to the
prominent work of the National Institutes of Health (NIH)
Task Force that recently published a report about minimum
baseline measures for clinical studies on chronic LBP [21].
Identification of existing knowledge
The Steering Committee identified initiatives that could
potentially overlap with this study at an early stage ofthis project. None of these initiatives had the same scope
as this COS. In this subsection, we report where partial
conceptual overlap between this COS and the other ini-
tiatives could lie:
1. The Initiative on Methods, Measurement, and Pain
Assessment in Clinical Trials (IMMPACT) has
developed a consensus-based set of outcome domains
and measurement instruments for clinical trials on
chronic pain [22,23]. IMMPACT leaves ample
space for the definition of more specialized COSs
for some specific subgroups of patients with pain,
such as this COS which focuses only on patients
with NSLBP.
2. A core set for LBP based on the International
Classification of Functioning (ICF) was developed by
linking the health issues associated with LBP to the
categories of the ICF framework [24]. These core
sets are available for use in clinical studies or to
guide assessment of patients with LBP, but they do
not have a specific focus on the measurement of
outcomes in clinical trials.
3. The recent NIH Task Force recommended baseline
research standards for clinical studies on chronic
LBP (CLBP) [21]. These recommendations are
proposed to describe, stratify, and compare reports
on patients with chronic LBP, but they are not
prescriptive for the reporting of core outcomes in
clinical trials.
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Measurement (ICHOM) has recently developed a
standardized set of outcomes for LBP [25]. The
ICHOM initiative aims at targeting ‘all providers
around the world’ and all LBP disorders. This
suggests a rather broad scope focused on the provision
of healthcare, rather than a specific focus on core
outcomes for all health interventions assessed in
clinical trials for NSLBP.Stakeholder involvement
Different stakeholders can be involved in the development
of a COS: researchers, healthcare providers, patients, man-
agers, government agencies, and industry representatives
[11]. The involvement of multiple stakeholders in the
consensus process for a COS is strongly recommended
by COS methodologists [11,16,26]. For this COS, the
Steering Committee decided to focus on four groups of
stakeholders:
1. Healthcare researchers: these are professionals working
in all fields of clinical research relevant for NSLBP
(such as orthopaedics, physiotherapy, psychology,
chiropractic, anaesthesiology, rheumatology, physical
medicine, and rehabilitation), methodologists, or
statisticians who currently work only as researchers.
All researchers involved in this project should be
authors of published scientific articles on clinical
research for LBP.
2. Healthcare providers: these are professionals from
different disciplines who have clinical experience in
the management of patients with NSLBP.
3. Professionals who work both as healthcare researchers
and providers: a separate category is made for these
professionals because they might bring a perspective
on core outcomes that may differ from that of people
who perform only one of the two jobs.
4. Patients: this group is composed of people who
have or have had NSLBP, and who sought healthcare
for their NSLBP. Previous research has shown that it
is limiting not to include patients in the development
of a COS [16]. Patients have the perspective of
living with the health condition and this may
substantially differ from those of researchers and
providers.
The decision to focus on these groups of stakeholders
was based on practical considerations related to the re-
sources of time and money available for the project. Mem-
bers of the Steering Committee represented all these
stakeholder groups, and representatives of each were
invited to participate in the Delphi study used to reach
consensus on this core domain set.A conceptual framework
A comprehensive framework of health can be beneficial
in developing a COS, favouring the content validity of the
end product. A recent review identified five conceptual
frameworks that could be relevant for COSs development
[27]. However, only the five Ds (discomfort, disability,
drug toxicity, dollar cost, and death) and the ICF frame-
work have been used to develop COSs in different health
areas, and they cover somewhat different areas of outcome
[27]. The OMERACT initiative has developed a new frame-
work that aims at including all key aspects of a health
condition to ensure comprehensiveness of COSs [17].
The OMERACT Filter 2.0 framework was created to
broaden the ICF framework and combine it with Wilson
and Cleary’s model of health-related quality of life [28].
The framework is subdivided into core areas (Table 1) that
encompass the complete content of what is measurable
in a clinical trial, including both patient-centred and
intervention-specific information. It includes three core
areas that describe the ‘impact of health conditions’
(‘death’, ‘life impact’, and ‘resource use and economic
impact’) and one core area that describes ‘pathophysio-
logical manifestations’. An explanation of the four core
areas of the OMERACT framework is presented in Table 2.
OMERACT recommends the inclusion of at least one do-
main from each core area in every COS [17]. However,
our Steering Committee decided that, initially, no require-
ments related to the core areas should be applied to the
domains that may become part of this core domain set.
Regarding ‘death’, it was noted that this is a mandatory
reporting requirement for all clinical trials, but a rare
event in NSLBP. Regarding ‘pathophysiological mani-
festations’, it was noted that they might be out of the
scope of some clinical trials, given that NSLBP is defined
by its lack of known pathophysiology. The Delphi study
will be used to evaluate whether substantial and convin-
cing arguments generate further discussion on this within
the Steering Committee. The OMERACT Filter 2.0 frame-
work was used by the Steering Committee to help the
development of a list of potential core domains and for
discussion during the Delphi study.Methods to reach consensus on a core domain set for
non-specific low back pain
A Delphi technique was used in this study, as in some
other COS efforts [26]. This method is usually used to
gain consensus among a group of experts or informed
respondents that constitute the Delphi panel [29]. The re-
spondents take part anonymously in sequential question-
naires that constitute different rounds. After each round,
the group responses are fed back to the panellists who can
reconsider their views based on this report of the group
views [29]. The Delphi method avoids situations in which
Table 2 OMERACT Filter 2.0 framework which specify all aspects of a health condition that should be considered in
clinical trials (Adapted from Boers et al. [17])
Core Area Specification
Deatha This core area includes possible specifications of death, such as generic or disease-specific (all-cause versus
disease-specific mortality), and intervention-specific (for example, death due to surgery).
Life Impacta This core area can include domains of the ICF [35] (such as activity and participation) and domains within
the concept of health-related quality of life [28] (such as functional status, general health perceptions, and
overall quality of life).
Resource Use/Economical Impacta This core area describes the economic impact of health conditions both on society and on the individual.
In fact, the presence of a health condition and its treatment incur resource use.
Pathophysiological Manifestationsb This core area is to assess whether or not the effect of the intervention specifically targets the pathophysiology
of the health condition. Pathophysiology can include psychosocial manifestations. Example domains are: ICF
body function, reversible manifestations (including modifiable risk factors and actual manifestations of ill health),
and irreversible manifestations (including unmodifiable risk factors and damage). This area can also encompass
all biomarkers and surrogate outcomes.
aThese core areas belong to the concept ‘impact of health conditions’ which includes all aspects of health or a health condition that are important to the patient
and society.
bThis core area belong to the concept ‘pathophysiological manifestations of health conditions’.
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personalities.
Before running the Delphi procedure, one member of
the project team (AC) selected the people who were in-
vited to be members of the panel. The project team and
the Steering Committee took responsibility for drawing a
list of potential core domains that was used in the Delphi
study. The pre-Delphi steps described in this subsection
have been completed, while the Delphi procedure itself is
nearing completion.
Selection of panel members
We decided that at least 80 experts were required to par-
ticipate in each round of the Delphi. Based on previous
experience with Delphi studies [14], we calculated a
minimum response rate of 40% that led to the conclu-
sion that at least 200 people had to be invited in the
first round. A list of researchers who had extensively
published on LBP was compiled using an approach aimed
at minimizing selection bias. First, a search in Web of
Science was performed to identify authors of at least 25
publications on LBP over the last 10 years (between 2003
and 2013). Those who were authors of at least two clinical
trials or one systematic review of clinical trials on NSLBP
were considered eligible. One reviewer (AC) screened ti-
tles and abstracts of publications of each author against
the inclusion criteria. Only researchers with a retrievable
email address were selected for invitation to the Delphi
procedure. To ensure that notable researchers were not
excluded from this list, convenience sampling was added
to the systematic search. Members of the Steering Com-
mittee were asked to indicate the names of five researchers
from different disciplines that should absolutely be in-
cluded in this consensus exercise. Names recommended
by the Steering Committee were added to the existing list.
Healthcare providers for the Delphi panel were recruited
through convenience sampling. Each member of theSteering Committee was asked to identify a minimum
of 10 clinicians from different disciplines who had clinical
experience in managing patients with NSLBP.
Patients were also recruited through convenience sam-
pling. Inclusion criteria for patients were: present or past
history of NSLBP, attendance of healthcare for their back
complaint, and fluent understanding of written English.
Three members of the Steering Committee from different
geographical locations (CL, MS, and RO) were asked to
identify providers who could have direct contact to pa-
tients. Patients identified by these providers were con-
tacted by email, provided further information about the
study, and invited to participate. Those who agreed were
sent an informative document giving explanations of
technical terms that could be encountered during the ques-
tionnaires. Those who confirmed their interest were invited
to take part in the Delphi study.
All members of the Steering Committee were also invited
to take part in the Delphi study. This implies that they
expressed their opinion twice regarding aspects dis-
cussed previously within the Steering Committee and then
in the Delphi study (for example, regarding AEs). It was
decided not to exclude their opinion from the Delphi re-
sults, where responses remained anonymous and could be
seen by the whole panel. We considered that this fact
could outweigh the disadvantage of having their opinion
counting twice for some issues. The final list of selected
panellists was known only to the project team member
who compiled it (AC), and was not shared with the Steer-
ing Committee or any other panellist.
Generation of a list of potential core domains
To make a list of (sub)domains that are routinely used
as outcomes in efficacy or effectiveness trials for NSLBP,
a search was performed of five recent Cochrane systematic
reviews) [8,30-32] (Oosterhuis T et al. unpublished data).
This first list of domains was subsequently enriched by
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core set for LBP [24] and in a conceptual model developed
to characterize the burden of LBP [33]. The comprehen-
sive ICF core set and the conceptual model on the burden
of LBP were adopted in this developmental phase because
they both considered the patients’ perspective [33,34].
Subdomains that seemed to cover the same domain were
grouped together to make a first draft list of domains
(version one) where domains were classified into one of
the core areas included in the OMERACT framework
(Table 2). To find appropriate terms and definitions for
each domain, we consulted the ICF Framework [35], the
Health Framework of the Patient-Reported Outcomes
Measurement Information System (PROMIS) [36], the
Wilson and Cleary Model [28], and IMMPACT [22,23].
When a definition was not found in one of these frame-
works, it was searched in individual published papers.
Different features of the version one list of domains were
discussed among the project team. A second literature
search based on points of discussion was conducted
and led to the development of the version two list. Feed-
back for version two was invited from other members of
the Steering Committee, who were asked to provide
critical comments on each domain. The members were
also asked to indicate if there were important missing
potential core domains and to indicate if they thought
that certain domains were too broad or should be aggre-
gated. The project team adjusted version two according to
this input and formulated the final list of potential core
domains (version three) that was used during the Delphi
study.
Delphi procedure
A minimum of two Delphi rounds (including both closed
and open-ended questions) was planned a priori. Consid-
ering that it is not feasible to weight responses from differ-
ent stakeholder groups, all panel members were invited to
participate, irrespective of the number from each stake-
holder group. Panel members were invited to participate
in each round of the Delphi study, unless they explicitly
indicated during the study that they did not wish to re-
ceive further invitations.
The project team designed the Delphi questionnaires,
sent invitations and reminders to panel members, analysed
the responses, and formulated the feedback reports.
Questionnaires used during the whole Delphi procedure
were pilot-tested by three members of the project team
(CT, MB, RO) and by one or two selected panellists. For
this Delphi study, the online software SurveyMonkey
(SurveyMonkey, Palo Alto, United States) was used and
invitations for participation were sent by email. Each
round was online for three or four weeks and reminder
emails were sent approximately every seven days after
the initial invitation. Recommendations of a group ofCOS methodologists for the use of the Delphi method
were followed in this study [26].
Delphi round one
In the first round, participants were initially given infor-
mation about the study and about the formulation of the
questionnaire. They completed questions about their edu-
cational and professional background, their experience
with clinical research relevant for NSLBP, and whether they
were invited to participate as patients. The version three
list of potential core domains, subdivided into core areas,
was used to rate their importance. In the survey, the order
of core areas and the order of domains within core areas
were randomized. Panel members were asked to indicate if
each domain was important enough to be included in this
core domain set; response options were ‘Yes’, ‘No’ and
‘Unsure/I do not know’. Participants were strongly en-
couraged to provide arguments for their choices and to
suggest modifications of definitions or wording of the
domains. Participants were then asked to indicate if they
considered that there was a large conceptual overlap be-
tween some domains, to suggest whether some domains
had be aggregated, and to suggest potential core domains
not included in the list. They were also asked to indicate
what they would consider to be an ideal number of
domains for this COS.
Finally, participants were asked to assess whether they
agreed on a specific approach for the reporting of AEs.
This approach highlighted that AEs cannot be considered
as one of the potential core domains because they could
affect multiple core areas and domains. Therefore, only
AEs occurring outside of core domains could be listed
specifically as AEs, because those occurring within a
defined core domain would be summarized within the
results for that domain. Panellists were asked to provide
reasons for their responses.
The responses of round one were analysed and collated
in the feedback report. Frequencies for the response
options on the importance of domains were calculated
for the whole panel. Responses to open questions were
checked to evaluate if substantial arguments emerged
against the overall trend of frequencies. Responses of
the patients’ group were highlighted and analysed separately
to assess if they differed from the other panel responses.
The project team established a priori that domains for
which more than 60% of the responders chose the response
option ‘No’ and less than 20% chose the response option
‘Yes’ would be dropped from the list of potential core do-
mains. The project team considered the suggestions for the
aggregation of certain domains and the strength of the ar-
guments. Suggested missing core domains were added to
the list for the next round. Descriptive statistics were used
to summarize responses on the ideal number of domains
and on the reporting of AEs.
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The feedback report was provided to the panel members
along with the second round of the survey. A proposal
was presented for deleting domains that did not have at
least 67% of first round respondents in favour or unsure
about inclusion in the core domain set. Other proposals
were driven by comments of the first round and concerned
exclusion, aggregation, or retention of other potential core
domains. For example, if in round one several comments
were made about the breadth of one domain covering
other more specific domains, a proposal was made to erase
this broad domain. Panellists were asked to indicate
whether or not they agreed with all the proposals and a
priori consensus was set at 67% respondent agreement.
Panellists were also asked to judge if missing core do-
mains suggested in the first round were important enough
to be included in the list. Response options were the same
as the first round and these domains were added to the list
of potential core domains if 67% of respondents were in
favour or unsure of their inclusion.
Upon completion of the second round, responses were
analysed and combined in the feedback report. As in the
first round, patients’ responses were analysed separately
to assess if they had different opinions from the rest of the
panel. Results were discussed by the project team, which
assessed whether substantial arguments emerged against
the overall consensus obtained with quantitative answers.
Delphi round three
The feedback report of the second round was presented
to all participants invited to the third round. Based on
previous results, the potential core domains left in the list
were presented in the third round to ask if each domain
was indeed core. Response options were the same as the
first round and participants were given the opportunity to
provide arguments for their choices.
Frequencies for the response options were calculated
for the whole panel and for each of the four stakeholder
groups separately to evaluate if discrepancies existed be-
tween the groups. Reasons for all choices were checked
to ensure that no convincing arguments were raised against
the dominating group response. A priori consensus was set
at 67% of the panel agreeing that a domain was core, with
domains reaching this threshold to be included in this
COS. If there were clear discrepancies between stake-
holder groups or controversial arguments emerged, the
results were presented to the Steering Committee that
made final decisions.
Ethical approval
As this project does not involve experiments with patients
or study subjects, according to the Dutch Medical Re-
search in Human Subjects Act (WMO), it is exempt from
ethical approval in The Netherlands. No ethical approvalis required in other countries from which other patients
were invited to take part in the Delphi study (United
States and Italy). All patients involved were asked for their
consent before participation in the Delphi study, and all
procedures were conducted according to the Declaration
of Helsinki.
Discussion
Development of a COS is an iterative approach that in-
cludes, firstly, determination of the domains that should
be measured and reported and, secondly, determination of
which outcome measurement instruments should be used
to measure the domains [11,17]. This study protocol pre-
sents the methodology that has been adopted for develop-
ment of a consensus-based core domain set for clinical
trials of health interventions for NSLBP. It forms the first
step in updating the proposal of standardized measure-
ment in LBP made in 1998 by Deyo et al. [13]. Conceptu-
alisation and design of the second step for this COS
will now need to be established, and recently published
methodological guidance [37,38] in this field could act
as a useful reference for formulating the core outcome
measurement set for NSLBP.
Trial status
The third round of the Delphi study has recently been
completed and the results will be analysed and reviewed
by the Steering Committee. A publication reporting the
results of the Delphi study will be submitted for publica-
tion in late 2014.
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